Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
2
×
Tags
biotech
clinical trials
europe blog main
2
×
europe top stories
fda
2
×
indiana blog main
indiana top stories
life sciences
national blog main
new york blog main
new york top stories
arena pharmaceuticals
boehringer ingelheim
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
cardiovascular disease
colorectal cancer
detroit blog main
detroit top stories
eisai
eli lilly
empagliflozin
europe
lorcaserin
lung cancer
national
national top stories
obsesity
orexigen therapeutics
pancreatic cancer
product recalls
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
What
drug
2
×
fda
patients
2
×
approval
bid
boehringer
cancer
diabetes
eisai
eli
expand
fallen
flags
higher
incidence
ingelheim
lilly
lorcaserin
loss
market
marketed
marketing
medicine
medicine’s
post
pulls
rejects
risks
short
study
took
type
weight
withdrawing
Language
unset
Current search:
drug
×
patients
×
fda
×
photo
×
" europe blog main "
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
